Clinical Trial Update: An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing 10 mg and 20 mg IMP4297 capsules in healthy Chinese subjects under fed conditions has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• IMP4297 (IMP4297)

Snippet

Sponsor: Impact Therapeutics, Inc. | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED